FUNDAMENTALS · Fundamentals · US Healthcare

Evolent Health (EVH) Fundamentals 2026 — Revenue Analysis | SniperIQ

Evolent Health (EVH) is a US-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of $629M, trading at $5.59 on the NYSE. This SniperIQ fundamentals page covers Evolent Health's valuation, profitability (net margin -26.3%), revenue (

.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$629M
Net Margin-26.3%
Revenue (FY25)
.9B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Evolent Health's market cap?

Evolent Health (EVH) has a market capitalization of approximately $629M, trading at $5.59 on the NYSE. Market cap moves with the live share price.

What is Evolent Health's P/E ratio?

Evolent Health's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Evolent Health?

Evolent Health runs a net profit margin of -26.3%, a gross margin of 14.1%, and an operating margin of -0.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Evolent Health generate?

Evolent Health reported revenue of

.9B for fiscal year 2025, with net income of -$535M and earnings per share (EPS) of -5.07. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Evolent Health pay a dividend?

Evolent Health does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Evolent Health financially healthy?

Evolent Health carries a debt-to-equity ratio of 2.49x and a current ratio of 1.32x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Evolent Health a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Evolent Health (EVH) the key facts are: market cap $629M, revenue

.9B, 52-week range 2.095-10.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Evolent Health's full fundamentals live

Get Evolent Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.